VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recruiting in Palo Alto (17 mi)

+66 other locations

Overseen byRobert Coleman

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: National Cancer Institute (NCI)

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial cancer cells.

Research Team

Robert Coleman

Principal Investigator

Gynecologic Oncology Group

Eligibility Criteria

Inclusion Criteria

Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

Platelet count ≥ 100,000/mm^3

Recurrent or persistent disease

See 7 more

Treatment Details

Interventions

ziv-aflibercept (VEGF Inhibitor)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (aflibercept)Experimental Treatment1 Intervention

Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.